Psychiatry Grand Rounds April 19, 2024
Glucagon-like peptide-1 (Glp1) receptor (Glp1r) agonists are drugs originally developed to treat type 2 diabetes but that are now also approved to treat obesity by promoting weight loss. This talk describes ongoing research in my lab focused on understanding the molecular mechanisms by which Glp1r agonists promote weight loss.
Julio Ayala, PhD
Associate Professor,
Department of Molecular Physiology & Biophysics,
Vanderbilt University School of Medicine
www.vumc.org/psychiatry/grand...
Objectives:
The activity is designed to help the learner:
1. Describe background information about the biology and clinical use of Glucagon-like peptide-1 receptor (Glp1r) agonists.
2. Discuss the importance of pre-clinical investigations on the mechanism of action of Glp1r agonists.
3. Describe pre-clinical research conducted in the Ayala lab focusing on molecular mechanisms mediating the weight loss effect of Glp1r agonists.
CME/CE credit for Psychiatry Grand Rounds is only available during the live feed time and for a brief time immediately following. The code for this week's session is displayed at the opening and closing of the meeting